| Literature DB >> 30513742 |
Máryury Flores-Sumoza1, Jackson J Alcázar2, Edgar Márquez3, José R Mora4, Jesús Lezama5, Esneyder Puello6.
Abstract
In this work, the minimum energy structures of 22 4-pyridone derivatives have been optimized at Density Functional Theory level, and several quantum molecular, including electronic and thermodynamic descriptors, were computed for these substrates in order to obtain a statistical and meaningful QSAR equation. In this sense, by using multiple linear regressions, five mathematical models have been obtained. The best model with only four descriptors (r² = 0.86, Q² = 0.92, S.E.P = 0.38) was validated by the leave-one-out cross-validation method. The antimalarial activity can be explained by the combination of the four mentioned descriptors e.g., electronic potential, dipolar momentum, partition coefficient and molar refractivity. The statistical parameters of this model suggest that it is robust enough to predict the antimalarial activity of new possible compounds; consequently, three small chemical modifications into the structural core of these compounds were performed specifically on the most active compound of the series (compound 13). These three new suggested compounds were leveled as 13A, 13B and 13C, and the predicted biological antimalarial activity is 0.02 µM, 0.03 µM, and 0.07 µM, respectively. In order to complement these results focused on the possible action mechanism of the substrates, a docking simulation was included for these new structures as well as for the compound 13 and the docking scores (binding affinity) obtained for the interaction of these substrates with the cytochrome bc1, were -7.5, -7.2, -6.9 and -7.5 kcal/mol for 13A, 13B, 13C and compound 13, respectively, which suggests that these compounds are good candidates for its biological application in this illness.Entities:
Keywords: DFT; computational study; molecular descriptors; nitrogen compounds
Mesh:
Substances:
Year: 2018 PMID: 30513742 PMCID: PMC6321536 DOI: 10.3390/molecules23123166
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical Structures of antimalarial compounds used in this work. (A): Atovaquone; (B): Clopidol, C: structural bases of 4-Pyridones derivatives study in this work. Numbering in (C) is arbitrary.
Figure 2Chemical structures of 4-pyridones studied in this work.
Values of the eight most important properties calculated and their respective values of antimalarial activity.
| Comp. | pIC50 | s | µe | µ | q2 | q7 | G | MR | ClogP |
|---|---|---|---|---|---|---|---|---|---|
| Clopidol | 4.70 | 3.32 | −0.15 | 8.85 | 0.04 | −0.65 | −1321.26 | 49.35 | 1.22 |
| 2 | 5.40 | 3.52 | −0.14 | 7.80 | 0.04 | −0.66 | −1175.99 | 81.12 | 4.63 |
| 3 | 4.96 | 3.57 | −0.14 | 7.71 | 0.05 | −0.72 | −1092.66 | 69.01 | 1.78 |
| 4 | 5.60 | 3.50 | −0.14 | 8.70 | 0.05 | −0.73 | −1552.26 | 73.82 | 2.49 |
| 5 | 7.30 | 3.57 | −0.14 | 9.02 | 0.04 | −0.70 | −1786.81 | 99.52 | 5.17 |
| 6 | 6.40 | 3.58 | −0.13 | 8.74 | 0.07 | −0.77 | −1783.26 | 98.95 | 4.38 |
| 7 | 7.22 | 3.66 | −0.13 | 8.00 | 0.06 | −0.75 | −1858.47 | 100.06 | 4.59 |
| 8 | 6.82 | 3.76 | −0.13 | 7.58 | 0.02 | −0.76 | −3510.40 | 98.07 | 4.02 |
| 9 | 7.40 | 3.68 | −0.13 | 8.13 | 0.01 | −0.75 | −3609.65 | 98.29 | 4.17 |
| 10 | 6.60 | 3.73 | −0.13 | 8.45 | −0.33 | −0.76 | −1398.87 | 95.27 | 3.79 |
| 11 | 7.40 | 3.67 | −0.13 | 8.41 | 0.02 | −0.76 | −3970.00 | 102.87 | 4.74 |
| 12 | 7.52 | 3.63 | −0.13 | 9.70 | 0.06 | −0.75 | −1858.47 | 100.06 | 4.59 |
| 13 | 7.52 | 3.63 | −0.13 | 9.60 | 0.01 | −0.76 | −3970.00 | 102.87 | 4.74 |
| 14 | 6.30 | 3.43 | −0.14 | 11.19 | −0.34 | −0.75 | −1276.32 | 96.43 | 3.96 |
| 15 | 7.22 | 3.47 | −0.14 | 11.36 | 0.05 | −0.74 | −1735.92 | 101.23 | 4.76 |
| 16 | 7.52 | 3.52 | −0.13 | 11.09 | −0.01 | −0.75 | −3847.46 | 104.04 | 4.91 |
| 17 | 7.52 | 3.51 | −0.13 | 10.97 | 0.06 | −0.75 | −1735.92 | 101.23 | 4.76 |
| 18 | 7.52 | 3.63 | −0.13 | 9.01 | 0.01 | −0.76 | −3886.75 | 109.08 | 5.41 |
| 19 | 6.80 | 3.63 | −0.13 | 10.48 | −0.34 | −0.75 | −1351.54 | 97.00 | 4.11 |
| 20 | 7.52 | 3.57 | −0.13 | 10.52 | 0.05 | −0.74 | −1811.14 | 101.79 | 4.90 |
| 21 | 7.52 | 3.59 | −0.13 | 10.36 | 0.00 | −0.75 | −3922.67 | 104.61 | 5.05 |
| 22 | 5.66 | 3.65 | −0.13 | 8.67 | −0.34 | −0.35 | −1474.02 | 0.00 | 3.69 |
S: softness; G = Gibbs Energy; µe: electronic chemical potential, (kcal/mol); MR: molar refractivity (cm3).
Correlated matrix for descriptors included in model 3.
| Parameter | pIC50 | ClogP | MR | µ | µe |
|---|---|---|---|---|---|
| pIC50 | 1.000 | 0.850 | 0.726 | 0.427 | 0.647 |
| ClogP | 0.850 | 1.000 | 0.606 | 0.352 | 0.597 |
| MR | 0.726 | 0.606 | 1.000 | 0.301 | 0.217 |
| µ | 0.427 | 0.352 | 0.301 | 1.000 | −0.035 |
| µe | 0.647 | 0.597 | 0.217 | −0.035 | 1.000 |
pIC50 = log(106/IC50); CLoP: Partition coefficient; MR: molar refractivity, µ: dipolar momentum; µe: Electronic potential.
Figure 3Experimental pIC50 vs predicted pIC50 using Equation (3).
Figure 4New possible small structure modification on the compound 13 and predicted IC50 values.
Figure 5Plot for the binding affinity versus pIC50.
Figure 6The new antimalarial structure predicted using Equation (3) and docking illustration using the 3D structure of cytochrome bc1 complex.